Astragaloside IV Alleviates Liver Inflammation, Oxidative Stress and Apoptosis to Protect Against Experimental Non-Alcoholic Fatty Liver Disease

Código QR

Astragaloside IV Alleviates Liver Inflammation, Oxidative Stress and Apoptosis to Protect Against Experimental Non-Alcoholic Fatty Liver Disease

Xiao-yu Liang,1 Fen-Fang Hong,2 Shu-Long Yang1 1Department of Physiology, College of Medicine, Nanchang University, Nanchang, 330006, People’s Republic of China; 2Experimental Teaching Center, Nanchang University, Nanchang, 330031, People’s Republic of ChinaCorrespondence: Shu-Lo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Liang XY, Hong Ff, Yang SL
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	astragaloside iv non-alcoholic fatty liver disease lipid accumulation oxidative stress apoptosis. Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/9c04d24d1f844b5e9681e2b6a9c1f542
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Astragaloside IV Inhibits Mitochondrial-Dependent Apoptosis of the Dorsal Root Ganglion in Diabetic Peripheral Neuropathy Rats Through Modulation of the SIRT1/p53 Signaling Pathway
por: Ben Y, et al.
Publicado: (2021)

Current concepts of the pathogenesis of non-alcoholic fatty liver disease
por: Evgenia Pavlovna Kosobyan, et al.
Publicado: (2010)

Research Progress on the Ability of Astragaloside IV to Protect the Brain Against Ischemia-Reperfusion Injury
por: Xianhui Kang, et al.
Publicado: (2021)

The Mechanism Actions of Astragaloside IV Prevents the Progression of Hypertensive Heart Disease Based on Network Pharmacology and Experimental Pharmacology
por: Haoran Jing, et al.
Publicado: (2021)

Body Mass Index and Indicators of Lipid Exchange in Liver Steatosis of Alcoholic and Nonalcoholic Genesis in Residents of Rural Area: Similarities and Differences
por: N. V. Mikhaylova, et al.
Publicado: (2019)

Non-Alcoholic Fatty Liver Disease and Hypothyroidism: Review of Clinical and Experimental Studies
por: Tetiana Ranhulova
Publicado: (2021)

Causes of death in patients with Non-alcoholic Fatty Liver Disease (NAFLD), alcoholic liver disease and chronic viral Hepatitis B and C
por: Pegah Golabi, et al.
Publicado: (2022)

The Role of Notch Signaling Pathway in Non-Alcoholic Fatty Liver Disease
por: Hao Xu, et al.
Publicado: (2021)

Accumulation of Genetic and Epigenetic Alterations in the Background Liver and Emergence of Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease
por: Satoru Hagiwara, et al.
Publicado: (2021)

Astragaloside IV Attenuates Ocular Hypertension in a Mouse Model of TGFβ2 Induced Primary Open Angle Glaucoma
por: Ramesh B. Kasetti, et al.
Publicado: (2021)

Diagnostics and treatment of non-alcoholic fatty liver disease with concomitant asthenic syndrome
por: Aleksandr I. Pavlov, et al.
Publicado: (2021)

Non-Alcoholic Fatty Liver Disease as a Risk for Colorectal Cancer Development and the Role of Screening Colonoscopy in Clinical Practice
por: Cosmas Rinaldi Adithya Lesmana, et al.
Publicado: (2019)

Diagnostic significance of clinical and laboratory indices in predicting non-alcoholic fatty liver disease during screening studies
por: Aleksandr E. Nosov, et al.
Publicado: (2021)

Astragaloside IV Protects from PM2.5-Induced Lung Injury by Regulating Autophagy via Inhibition of PI3K/Akt/mTOR Signaling in vivo and in vitro
por: Pei C, et al.
Publicado: (2021)

(+)-Dehydrovomifoliol Alleviates Oleic Acid-Induced Lipid Accumulation in HepG2 Cells via the PPARα–FGF21 Pathway
por: Yiyuan Xi, et al.
Publicado: (2021)

Verapamil induces autophagy to improve liver regeneration in non-alcoholic fatty liver mice
por: Jian-Lin Lai, et al.
Publicado: (2021)

The Contribution of Dietary Fructose to Non-alcoholic Fatty Liver Disease
por: Siyu Yu, et al.
Publicado: (2021)

Adiponutrin and Adiponectin Gene Variants in Indonesian Patients with Non-Alcoholic Fatty Liver Disease: a Preliminary Study
por: Rayvita AN Meagratia, et al.
Publicado: (2021)

Activation and Functional Priming of Blood Neutrophils in Non-Alcoholic Fatty Liver Disease Increases in Non-Alcoholic Steatohepatitis
por: Lauszus JS, et al.
Publicado: (2021)

Metformin treatment reverses high fat diet- induced non-alcoholic fatty liver diseases and dyslipidemia by stimulating multiple antioxidant and anti-inflammatory pathways
por: Tahmina Yasmin, et al.
Publicado: (2021)

Lipid Metabolism Disorders in the Comorbid Course of Nonalcoholic Fatty Liver Disease and Chronic Obstructive Pulmonary Disease
por: Stanislav Kotlyarov, et al.
Publicado: (2021)

Obesity and nonalcoholic fatty liver disease: current perspectives
por: Sarwar R, et al.
Publicado: (2018)

SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions
por: Gharaibeh NE, et al.
Publicado: (2019)

Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets
por: Daniela Maria Tanase, et al.
Publicado: (2021)

Integrative lipidomic and transcriptomic study unravels the therapeutic effects of saikosaponins A and D on non-alcoholic fatty liver disease
por: Xiaojiaoyang Li, et al.
Publicado: (2021)

Varied Relationship of Lipid and Lipoprotein Profiles to Liver Fat Content in Phenotypes of Metabolic Associated Fatty Liver Disease
por: Tingfeng Wu, et al.
Publicado: (2021)

Clinical and Metabolic Characteristics of Non-Alcoholic Fatty Liver Disease Patients in Saudi Arabia: Data from the Systematic Observatory Liver Disease (SOLID) Registry
por: Alswat K, et al.
Publicado: (2021)

PRESENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS OF UNCONTROLLED AND CONTROLLED TYPE 2 DIABETES MELLITUS
por: Aqeela Rashid, et al.
Publicado: (2019)

Non-invasive Diagnostics of Liver Fibrosis
por: Mihaylov R., et al.
Publicado: (2017)

Non-Alcoholic Fatty Liver Disease (NAFLD) and Potential Links to Depression, Anxiety, and Chronic Stress
por: Sue Shea, et al.
Publicado: (2021)

Effect of Saxagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Non-Alcoholic Fatty Liver Disease
por: Chen L, et al.
Publicado: (2020)

Activation of TAF9 via Danshensu-Induced Upregulation of HDAC1 Expression Alleviates Non-alcoholic Fatty Liver Disease
por: Ruiwen Wang, et al.
Publicado: (2021)

Impact of Genetic Polymorphism on Response to Therapy in Non-Alcoholic Fatty Liver Disease
por: José Ignacio Martínez-Montoro, et al.
Publicado: (2021)

Inadequate identification of fatty liver disease, obesity, and metabolic syndrome by family physicians
por: Mahamid M, et al.
Publicado: (2018)

Total polyunsaturated fatty acid intake and the risk of non-alcoholic fatty liver disease in Chinese Han adults: a secondary analysis based on a case–control study
por: Yong Xie, et al.
Publicado: (2021)

High-Normal Serum Thyrotropin Levels Increased the Risk of Non-Alcoholic Fatty Liver Disease in Euthyroid Subjects with Type 2 Diabetes
por: Tan Y, et al.
Publicado: (2021)

Liver biopsy in the quantitative assessment of liver fibrosis in nonalcoholic fatty liver disease
por: Gwyneth Shook Ting Soon, et al.
Publicado: (2021)

Astragalus Polysaccharides and Saponins Alleviate Liver Injury and Regulate Gut Microbiota in Alcohol Liver Disease Mice
por: Jingxuan Zhou, et al.
Publicado: (2021)

Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: From Epidemiology to Diagnostic Approach
por: Ivica Grgurevic, et al.
Publicado: (2021)

Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial
por: Fatemeh Naeini, et al.
Publicado: (2021)